Skip to content
Disclosery

Consonance Capital Management LP

Follow

13F filer, CIK 1544773, New York, NY

Consonance Capital Management LP reported $23,713,000 across 7 holdings for the quarter ended 2022-06-30, in a 13F-HR filed 2022-08-15.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001085146-22-003049

Period
2022-06-30
Reported value
$23.7M
Holdings
7
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TNDMreduced-143,033-$8.46M
GMEDreduced-101,619-$5.7M
UTHRreduced-21,565-$5.08M
CMPXreduced-1,896,211-$4.99M
MOONLAKE IMMUNOTHERAPEUTICSexited-137,000-$1.52M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2022

Share positions as resolved from 13F-HR 0001085146-22-003049, largest first. % of portfolio is the value over $23,713,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
Surrozen, Inc.Surrozen, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: 1,000,000 shares; 2021Q4: 3,497,500 shares; 2022Q1: 3,497,500 shares; 2022Q2: 3,497,500 shares 3,497,500$10.5M44.25%0
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: 222,222 shares; 2021Q2: 222,222 shares; 2021Q3: 178,787 shares; 2021Q4: 758,253 shares; 2022Q1: 654,108 shares; 2022Q2: 634,270 shares 634,270$7.52M31.7%-19,838Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: not reported; 2021Q4: 3,500,000 shares; 2022Q1: 3,500,000 shares; 2022Q2: 1,603,789 shares 1,603,789$4.22M17.79%-1,896,211Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: 528,964 shares; 2021Q1: 558,162 shares; 2021Q2: 159,087 shares; 2021Q3: 157,838 shares; 2021Q4: 59,838 shares; 2022Q1: 24,563 shares; 2022Q2: 2,998 shares 2,998$706K2.98%-21,565Timeline
GMEDGLOBUS MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: 908,953 shares; 2021Q1: 578,371 shares; 2021Q2: 1,084,979 shares; 2021Q3: 589,100 shares; 2021Q4: 373,254 shares; 2022Q1: 107,024 shares; 2022Q2: 5,405 shares 5,405$303K1.28%-101,619Timeline
TNDMTANDEM DIABETES CARE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: 979,226 shares; 2021Q3: 487,327 shares; 2021Q4: 300,664 shares; 2022Q1: 147,327 shares; 2022Q2: 4,294 shares 4,294$254K1.07%-143,033Timeline
SRZNWSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: 333,333 shares; 2021Q4: 1,165,832 shares; 2022Q1: 1,165,832 shares; 2022Q2: 1,165,832 shares 1,165,832$223K0.94%0Timeline

Sold out in Q2 2022

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
MOONLAKE IMMUNOTHERAPEUTICSMOONLAKE IMMUNOTHERAPEUTICS137,000$1.52Mshares

How Q2 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001085146-22-003049 base2022-08-15acceptance time not in the bulk data set